Jeremy Braybrooke

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial

Nicholas C. Turner, Belinda Kingston, Lucy Kilburn et al. · The Lancet Oncology · 2020 · 334 citations · Full text

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

Stephen Johnston, Lucy Kilburn, David Dodwell et al. · The Lancet Oncology · 2013 · 272 citations · Full text

Phase I and Pharmacokinetic Study of PKC412, an Inhibitor of Protein Kinase C

David Propper, A. McDonald, A. Man et al. · Journal of Clinical Oncology · 2001 · 233 citations

A Phase II Study of Etanercept (Enbrel), a Tumor Necrosis Factor α Inhibitor in Patients with Metastatic Breast Cancer

Srinivasan Madhusudan, Martin D. Foster, S. Muthuramalingam et al. · Clinical Cancer Research · 2004 · 203 citations · Full text